Figure 4: MK-1064 effectively promotes somnolence but not cataplexy in canines.
From: Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man
(a) Mean time (±SEM) in active wake, NREM I, NREM II, and REM sleep of dogs in the 1 hour following active-phase administration of vehicle (sodium citrate 10 mM, orally) or MK-1064 1 mg/kg (N = 6, ZT 03:00) or 20 mg/kg (N = 8, ZT 04:00) (linear mixed-effects model for repeated measures ANOVA; **, ***p < 0.05 < 0.001, respectively; t test). (b) In coincident analysis, the mean duration (±SEM) to complete FECT following administration of vehicle (sodium citrate 10 mM, orally) or MK-1064 (20 mg/kg) 1 hour after dose administration showed no significant difference between conditions (N = 8, paired t-test).
